How Telehealth and AI Integration Increase Medical Practice Valuation Multiples

Telehealth and artificial intelligence can make a medical practice more valuable, but not because technology creates a premium by itself. In a professional business valuation, telehealth, remote patient monitoring, AI-assisted documentation, revenue-cycle analytics, clinical decision support, patient engagement tools, and interoperable health IT matter only when they change the economics or risk profile of the practice. A buyer, lender, court, partner, or appraiser will want to see whether those tools increase recurring revenue, improve provider capacity, reduce administrative friction, strengthen documentation, support collections, improve patient retention, reduce operational risk, or make the practice easier to integrate after a transaction.

That is the central answer behind the headline. Telehealth and AI integration may support stronger medical practice valuation multiples when the practice can prove measurable, transferable benefits. They may do nothing for value if adoption is weak. They may reduce value if they create billing risk, cybersecurity exposure, vendor lock-in, recurring cost, clinician resistance, or unsupported add-backs. The valuation question is not, “Does the practice use AI?” The better question is, “Can the practice connect digital capability to supportable cash flow, lower risk, scalable operations, and buyer confidence?”

This article explains how to make that connection without relying on unsupported market multiple claims. It covers telehealth value drivers, AI value drivers, EBITDA normalization, discounted cash flow modeling, the market approach, the asset approach, due diligence evidence, risk controls, practical checklists, hypothetical case studies, and questions to ask before using technology as a valuation story. It also explains why a formal business appraisal should be prepared before an owner assumes that a digital workflow will translate into a higher valuation multiple.

Educational note: this article is valuation education for business owners and advisers. It is not legal, tax, reimbursement, coding, privacy, cybersecurity, medical, regulatory, investment, or transaction advice. Medical practices should coordinate with qualified healthcare counsel, ERISA or tax counsel where relevant, CPAs, coding advisers, compliance professionals, payers, technology vendors, and transaction advisers before relying on legal or regulatory conclusions.

Quick answer: can telehealth and AI increase medical practice valuation multiples?

Yes, telehealth and AI can support stronger medical practice valuation multiples, but only when the technology is adopted, documented, compliant with the practice’s applicable obligations, economically useful, and transferable. A valuation multiple is shorthand for expected earnings quality, growth, risk, and comparability. If telehealth expands patient access and sustains collectible revenue, or if AI-assisted workflows improve provider capacity after recurring costs and controls, the practice may support a stronger valuation conclusion than a comparable practice with lower growth, weaker data, or more operational risk.

The reverse is also true. A practice that buys software but cannot demonstrate usage, reimbursement durability, revenue capture, coding controls, provider acceptance, patient acceptance, data export rights, cybersecurity safeguards, or vendor transferability may not receive any valuation benefit. In diligence, the buyer or valuation analyst may treat those tools as costs, risks, or unproven initiatives rather than sources of enterprise value.

The most defensible valuation narrative is conditional:

• Telehealth can support value when it creates documented patient access, care-continuity, scheduling, revenue, and retention benefits.
• AI can support value when it improves documentation, coding, revenue-cycle analytics, patient intake, staff productivity, clinical workflow support, or decision support with human oversight and governance.
• EBITDA must be normalized for recurring software, support, cybersecurity, compliance, quality assurance, and replacement labor.
• A discounted cash flow model can test whether digital initiatives change future cash flow after adoption, reimbursement, investment, and risk are considered.
• The market approach can reflect digital capability only when comparable evidence, normalized EBITDA, and deal terms support the selected multiple.
• The asset approach may matter where technology infrastructure, medical devices, software implementation, working capital, or digital assets are material.

The important caution is that there is no reliable basis to publish a universal “telehealth premium” or “AI premium” for medical practice valuation multiples. The AMA’s digital-health research supports widespread physician adoption of digital tools, including a sharp increase in reported use of tele-visits/virtual visits by 2022, but adoption data is not valuation multiple evidence (American Medical Association, 2022). Medicare telehealth coverage and service-list rules are also policy-sensitive, and Medicare should not be generalized to every commercial payer, Medicaid program, state licensure rule, prescribing rule, consent rule, or malpractice issue (Centers for Medicare & Medicaid Services, n.d.-a; Cottrill et al., 2026).

Professional valuation CTA: verify the digital premium before you rely on it

If your medical practice is preparing for a sale, partner buyout, lender review, divorce, shareholder dispute, estate plan, compensation planning project, or strategic planning exercise, do not assume that telehealth or AI will automatically raise the multiple. Ask for a professional valuation that connects the technology story to financial statements, contracts, EHR reports, payer evidence, utilization data, cybersecurity documentation, governance policies, and normalized EBITDA.

Simply Business Valuation helps medical practice owners, attorneys, CPAs, lenders, and advisers evaluate whether digital initiatives are actually reflected in the valuation analysis. A defensible valuation can test adjusted EBITDA, discounted cash flow scenarios, market approach comparability, asset approach support, and overall business appraisal documentation. The result is not a guarantee of buyer price or transaction terms, but it can help owners enter negotiations with a clearer, evidence-based understanding of value.

What telehealth and AI integration means in a medical practice

Telehealth is more than a video visit link

For valuation purposes, telehealth is not merely a video platform. It can include virtual visits, online scheduling, digital intake, secure patient communications, patient portal workflows, remote patient monitoring, clinical follow-up protocols, virtual triage, medication management, behavioral health sessions, post-procedure checks, specialist consults, and documentation/billing procedures. The valuation analyst needs to know how those capabilities function inside the practice, not just whether the practice subscribes to a platform.

Official CMS telehealth resources describe Medicare telehealth processes and service-list context, including the fact that additions or deletions to Medicare telehealth services are handled through the annual physician fee schedule process and are effective on a January 1 basis (Centers for Medicare & Medicaid Services, n.d.-a). CMS also maintains a list of services payable under the Medicare Physician Fee Schedule when furnished via telehealth (Centers for Medicare & Medicaid Services, n.d.-b). KFF’s Medicare telehealth explainer provides secondary context on how pandemic-era flexibilities, utilization, and expiration timing have evolved, but it is not a substitute for current CMS rules or payer-specific review (Cottrill et al., 2026).

For a medical practice valuation, the telehealth questions are practical:

• Which services are offered remotely?
• Which providers use the workflow?
• How much of total visit volume and revenue comes from telehealth?
• Which payers reimburse the services, and at what collection rate?
• Are denials, refunds, and recoupments tracked by modality?
• Is telehealth revenue incremental or merely a substitute for existing office visits?
• Are documentation, coding, consent, patient communication, and platform contracts organized for diligence?
• Can the workflow transfer to a buyer, new provider group, or successor owner?

Those questions influence business valuation because they determine whether telehealth is a durable value driver or just an operating feature.

AI integration includes different tools with different risks

AI integration is also not one thing. A small practice may use AI-enabled appointment reminders, call center support, patient messaging, intake forms, prior authorization support, revenue-cycle analytics, ambient documentation, coding suggestions, quality reporting, marketing analytics, or dashboard tools. A specialty practice may use clinical decision support or an AI-enabled medical device. A larger group may use predictive analytics, referral management, scheduling optimization, and generative AI policies across multiple locations.

The AMA uses the term “augmented intelligence” to emphasize AI’s supportive role in medicine rather than a replacement of physicians. Its AI resources discuss oversight, transparency, physician liability, data privacy, cybersecurity, payer use of AI, and automated decision-making (American Medical Association, n.d.-a). That framing is useful for valuation because it keeps the analysis focused on supported workflows, human oversight, and measurable outcomes rather than hype.

Some AI-enabled tools raise regulatory-scope questions. The FDA maintains an AI-enabled medical-device list intended to identify AI-enabled medical devices authorized for marketing in the United States and to provide transparency to innovators, providers, and patients; the FDA also notes that the list is not comprehensive (U.S. Food and Drug Administration, n.d.-a). The FDA’s clinical decision support guidance explains that certain software functions may be excluded from the device definition while other software functions continue to fall under FDA digital-health policies if they meet the definition of a device (U.S. Food and Drug Administration, 2026). A valuation article should not decide whether a specific tool is regulated. It should identify the issue as a diligence item for qualified advisers.

Integration is the valuation issue, not the label

A practice does not become more valuable simply because its marketing materials mention “AI” or “virtual care.” Integration means the tool is embedded in actual workflow, adopted by providers and staff, reconciled to financial reporting, supported by contracts, reviewed for privacy and cybersecurity, and transferable. Evidence may include usage logs, training records, EHR interfaces, vendor agreements, audit logs, QA review, billing reports, denial history, patient communications, data export terms, service-level agreements, renewal pricing, incident history, and standard operating procedures.

For valuation methods, integration matters because it affects both numerator and denominator. It affects the numerator by changing expected revenue, EBITDA, and cash flow. It affects the denominator by changing risk, discount-rate support, market comparability, buyer confidence, and required remediation. A tool that improves documentation but requires recurring quality review and cybersecurity investment may still be valuable, but only after those recurring costs are reflected in normalized EBITDA and free cash flow.

Medical-practice buyer context: why digital capability matters in a consolidating market

Practice ownership and practice size have shifted

Medical practice ownership and size have changed over the last decade. An AMA practice-arrangement report states that the share of physicians in practices wholly owned by physicians fell from 60.1% in 2012 to 46.7% in 2022. The report also states that the share of physicians in practices with 10 or fewer physicians fell from 61.4% in 2012 to 51.8%, while physicians in practices with 50 or more physicians increased from 12.2% to 18.3%. It also reports that 4.5% of physicians belonged to a practice owned by a private equity group in 2022 (American Medical Association, n.d.-b).

Those figures do not prove valuation multiples, and they should not be used as pricing evidence. They do, however, help explain why buyers and appraisers care about systems. Larger groups, hospital-owned practices, private-equity-backed platforms, strategic consolidators, and sophisticated independent groups often care about repeatable workflows, clean data, provider productivity, payer documentation, scalable management processes, and integration readiness. Digital capability can matter because it may make a practice easier to operate, compare, finance, or integrate.

Platform buyers care about transferable systems

A digitally mature medical practice may be more attractive when its systems can be transferred to a buyer without excessive disruption. That does not mean every buyer will value the same system. A buyer with its own EHR, scheduling, or revenue-cycle platform may value clean data export and documented workflows more than the seller’s specific software contract. A hospital or large group may care about information-sharing procedures, interface maps, data quality, cybersecurity controls, and patient-record migration. A specialty platform may care about whether remote monitoring, AI-enabled diagnostics, or virtual follow-up programs can be scaled across additional locations.

A practice that has clean dashboards, documented workflows, and consistent provider adoption may reduce diligence friction. A practice with fragmented tools, one-person knowledge, nonassignable licenses, inconsistent templates, or unsupported add-backs may create integration costs. That is where valuation multiples can move: not because the buyer pays for a software brand, but because the buyer perceives lower risk, better scalability, or higher future cash flow.

Regulatory scrutiny can influence buyer behavior and timing

Healthcare transactions also operate in an environment of increasing public and regulatory attention. FTC, DOJ, and HHS materials have described federal inquiry into healthcare corporate dealmaking and private-equity involvement, while FTC and DOJ materials have also discussed serial acquisitions and roll-up strategies across the economy (Federal Trade Commission, 2024a, 2024b). The 2023 Merger Guidelines provide a broader antitrust framework for how federal agencies analyze certain mergers (Federal Trade Commission & U.S. Department of Justice, 2023).

A valuation should not assert that a specific practice transaction violates antitrust law or that a buyer will be blocked. It can, however, consider whether regulatory scrutiny, buyer type, deal structure, closing risk, timing, financing, and integration assumptions affect value. For example, if a digital platform strategy depends on acquiring many similar practices, buyers may conduct more careful diligence around market position, data rights, patient access, coding practices, quality controls, and corporate-practice issues. Those topics can influence risk and transaction structure even when they do not directly change EBITDA.

How valuation multiples actually move: cash flow, growth, risk, and comparability

Multiples are shorthand, not magic

A valuation multiple is not an independent source of value. It is a shorthand for a deeper valuation judgment about earnings quality, growth, risk, comparability, and expected return. In a medical practice valuation, EBITDA may be used as a transaction shorthand, but it can be misleading if not normalized for provider compensation, owner compensation, billing denials, software costs, cybersecurity spending, one-time implementation expense, recurring technology support, and the cost of replacing seller-dependent labor.

A higher multiple is more defensible when the practice has stronger evidence of transferable earnings and lower risk. A lower multiple is more defensible when the practice has unstable reimbursement, weak documentation, high provider dependence, poor cybersecurity, fragile technology, or unproven growth. Telehealth and AI influence the multiple only through those valuation fundamentals.

Digital integration can support stronger multiples through four channels

There are four practical channels through which telehealth and AI can support a stronger valuation result:

1. Revenue growth and retention. Telehealth can make appropriate follow-up care easier for patients, support access, reduce scheduling friction, or improve continuity in certain service lines. Patient engagement tools may reduce no-shows or improve patient communications. AI-enabled analytics may help identify referral, scheduling, or care-gap opportunities. These benefits matter only if they are visible in visit volume, collections, retention, referral conversion, or patient behavior.
2. Margin quality. AI documentation, coding support, workflow automation, digital intake, and revenue-cycle analytics may reduce administrative burden, improve note timeliness, decrease avoidable denials, or create provider capacity. The valuation must include recurring software, training, IT, compliance, QA, and cybersecurity costs before treating those benefits as EBITDA improvement.
3. Risk reduction. Governance, cybersecurity, interoperability, payer documentation, audit logs, and vendor controls can reduce uncertainty. The NIST AI Risk Management Framework, for example, identifies trustworthy AI characteristics and organizes risk-management activity around Govern, Map, Measure, and Manage functions (National Institute of Standards and Technology, 2023a, 2023b). A buyer may view a governed AI workflow differently from unmanaged generative AI use.
4. Scalability and comparability. Digital systems may make a practice more comparable to platform-quality targets if workflows are standardized, data is clean, and contracts transfer. Conversely, a practice may be less comparable if its technology is ad hoc, undocumented, or incompatible with buyer systems.

Digital integration can also reduce value

Technology can reduce value when it adds recurring cost without measurable use, creates payer or coding uncertainty, increases cybersecurity exposure, frustrates clinicians, generates patient complaints, locks the practice into nonassignable vendor contracts, or depends on one internal champion. The valuation analyst should be willing to model upside and downside. A thoughtful business appraisal may show that digital investment improves value after a certain adoption point, but is a cost drag before that point.

Visual aid 1: Telehealth and AI value-driver matrix

The following matrix is a valuation bridge. It does not create a formula or promise a premium. It shows how an appraiser or buyer can connect operational evidence to financial statement effects and valuation reasoning.

Capability	Operating metric to request	Potential financial-statement impact	Potential valuation impact	Diligence evidence
Virtual visits	Visit volume by modality, provider, payer, specialty, and month	Revenue mix, collections, provider capacity, support costs	May support growth if utilization and reimbursement are durable	Scheduling reports, payer policies, coding records, denial history
Remote patient monitoring or digital follow-up	Enrolled patients, adherence, escalation logs, collections, staff time	Program revenue, staffing cost, technology expense	May support recurring revenue or retention if clinically and financially supported	Protocols, logs, payer support, staffing schedules, patient records
Patient engagement tools	Portal use, reminder performance, no-show rates, cancellation rates	Revenue retention, scheduling efficiency, staff workload	May reduce volatility if patient behavior improves	EHR/portal reports, cancellation reports, complaint logs
Ambient documentation or AI note support	Provider adoption, note completion time, QA exceptions	Provider capacity, subscription cost, documentation quality	May improve margin quality if productivity gains exceed recurring costs	Vendor contract, training records, audit logs, QA review
AI coding or revenue-cycle analytics	Denial rate, days in A/R, coding audits, collections, payer inquiries	Revenue capture, audit cost, denial reserves	May increase buyer confidence if controls reduce billing uncertainty	Coding policies, audit results, payer correspondence, A/R reports
Clinical decision support	Alert use, override rates, governance review, patient safety workflow	Quality/risk implications, training cost, workflow cost	May reduce or increase risk depending on governance and use	CDS policies, review logs, ONC SAFER-style assessment, counsel review
AI-enabled medical devices	Device type, authorization status, use case, service-line volume	Equipment/software cost, service-line revenue	May support service-line economics if use is transferable	FDA database entry, service records, contracts, quality review
Interoperability and data access	Interface inventory, data-export ability, information-sharing process	Integration cost, diligence efficiency	Can reduce integration risk and support buyer confidence	Data maps, vendor terms, EHR/PM interface records
Cybersecurity and ePHI safeguards	Risk assessment, access controls, incident history, vendor access	Remediation cost, insurance, business continuity risk	Weak controls can reduce value; strong controls can reduce uncertainty	Security policies, incident logs, vendor security review, remediation plan

Telehealth value drivers in medical practice valuation

Patient access, convenience, and continuity

Telehealth can improve value when it supports appropriate patient access and care continuity. Behavioral health follow-ups, chronic-care check-ins, post-procedure checks, medication management, specialist consultations, and triage may be more convenient in a virtual format for certain patients and services. The FAIR Health Monthly Telehealth Regional Tracker uses commercial claims data to track telehealth on a monthly basis and includes categories such as telehealth claim-line trends, diagnostic categories, mental health diagnoses, specialties, age distribution, and place-of-service cost comparisons (FAIR Health, n.d.). That type of utilization context shows why modality tracking matters, although a practice valuation still needs practice-specific financial and operational data.

The appraiser should not assume that patient convenience equals enterprise value. The valuation file should show whether telehealth changed actual performance. Useful evidence includes monthly virtual visit count, revenue by payer, collection rates, denial rates, no-show changes, patient retention, patient satisfaction, referral patterns, provider capacity, and incremental versus substitute volume. A practice that moves existing visits from office to video without increasing collections, reducing costs, or improving retention may not have created incremental value.

Provider capacity and scheduling efficiency

Telehealth may improve provider capacity if it reduces downtime, supports shorter appropriate follow-ups, enables flexible scheduling, or expands access to patients who otherwise would miss visits. However, the capacity effect must be measured. A buyer will ask whether the practice increased billable capacity or merely changed visit modality. The valuation should separate gross revenue from net contribution after platform fees, staff support, documentation time, billing effort, denials, compliance review, and cybersecurity costs.

Capacity also intersects with physician compensation. If a physician-owner absorbs extra virtual visits without market compensation, reported EBITDA may overstate transferable earnings. In a professional medical practice valuation, replacement provider compensation and post-closing employment economics often matter as much as reported profit. Telehealth-driven capacity should be evaluated after normalizing provider pay and administrative burden.

Reimbursement durability and payer mix

Reimbursement durability is one of the most important telehealth valuation issues. CMS resources provide official Medicare telehealth process and list context, while KFF explains that Medicare telehealth flexibilities have been extended and changed over time (Centers for Medicare & Medicaid Services, n.d.-a, n.d.-b; Cottrill et al., 2026). KFF reported that traditional Medicare telehealth use rose dramatically early in the COVID-19 public health emergency and later declined while remaining above pre-pandemic levels; it also reported that Congress has repeatedly extended several pandemic-era telehealth flexibilities (Cottrill et al., 2026). Those statements support the broader point: reimbursement is policy-sensitive and should be current as of the valuation date.

A practice-specific valuation should review payer contracts, payer policies, denials, refunds, recoupments, documentation controls, billing practices, and any payer audit history. Medicare policy should not be treated as a proxy for commercial payer, Medicaid, state licensure, prescribing, consent, privacy, or malpractice requirements. When a meaningful portion of revenue comes from telehealth, the valuation should include reimbursement scenario analysis.

Telehealth data that should be in the valuation file

A medical practice owner who wants telehealth to support valuation should prepare a clear evidence package:

• Telehealth revenue by month, provider, location, payer, service category, and specialty.
• Virtual visit counts and virtual visits as a percentage of total visits.
• In-office versus virtual collection rates.
• Denials, refunds, recoupments, write-offs, and payer inquiries by modality.
• Patient no-show and cancellation trends before and after implementation.
• Patient retention, referral conversion, complaint logs, and satisfaction data where available.
• Documentation templates, coding policy, consent workflow, and billing training records.
• Platform contracts, renewal pricing, assignment terms, termination terms, data export rights, and security documentation.
• Remote monitoring protocols, patient enrollment, adherence, escalation logs, staffing requirements, collections, and denials.
• Counsel or compliance adviser review for licensure, prescribing, consent, privacy, payer, and state-law issues where applicable.

This evidence does not guarantee a higher multiple, but it gives the appraiser and buyer the support needed to evaluate whether telehealth has changed the practice’s cash flow and risk.

AI integration value drivers in medical practice valuation

Documentation, coding, and revenue-cycle AI

Many medical practices first encounter AI through documentation, coding support, and revenue-cycle analytics. These tools may support value if they improve note timeliness, reduce after-hours documentation burden, improve coding consistency, reduce avoidable denials, shorten billing lag, or improve collections. The AMA’s AI resources highlight governance, transparency, privacy, cybersecurity, payer use of AI, and automated decision-making as key physician-facing concerns (American Medical Association, n.d.-a). For valuation, those concerns translate into diligence questions.

A buyer will ask whether AI-supported documentation is accurate, reviewed, and accepted by providers. A payer or compliance reviewer may care about whether coding suggestions are audited and whether final coding decisions are appropriately supervised. A valuation analyst will ask whether the tool’s financial benefit exceeds recurring subscription fees, staff review, provider training, implementation time, QA review, cybersecurity, and vendor management. AI does not improve EBITDA unless the benefit remains after these costs.

Patient intake, engagement, scheduling, and triage

AI-assisted intake, reminders, chat, scheduling, call routing, and patient messaging may affect patient access and staff productivity. In valuation, the evidence should be concrete: appointment conversion, call abandonment, response time, staff overtime, no-shows, patient complaints, escalation protocols, clinician oversight, and patient retention. If a chatbot reduces call volume but creates patient dissatisfaction or unresolved clinical escalations, it may increase risk. If AI scheduling improves capacity but the benefit disappears when one manager leaves, it may not be transferable.

Triage tools deserve particular caution. A valuation should not make clinical safety claims unless supported by appropriate evidence and reviewed by qualified clinical and regulatory advisers. The appraiser can evaluate risk and transferability without rendering medical or legal conclusions.

Clinical decision support and AI-enabled medical devices

Clinical decision support and AI-enabled medical devices can be valuable in specialty practices, but the valuation analysis must be specific. The FDA’s AI-enabled medical-device list is designed to identify AI-enabled medical devices authorized for marketing in the United States and provide transparency; the FDA notes the list is not comprehensive (U.S. Food and Drug Administration, n.d.-a). FDA clinical decision support materials also distinguish software functions that may be excluded from the device definition from software functions that meet the definition of a device (U.S. Food and Drug Administration, 2026).

For valuation, the relevant questions are practical: Does the tool support a service line with measurable revenue? Is the tool transferable? Are contracts assignable? Are clinicians trained? Are quality reviews documented? Are there service records, device documentation, or vendor updates? Does the tool require equipment financing, subscription fees, data rights, or specialized staffing? If a device or workflow is central to a service line, both the income approach and asset approach may need to address it.

AI governance as a valuation risk reducer

AI governance can reduce valuation uncertainty. The NIST AI Risk Management Framework describes trustworthy AI characteristics such as validity and reliability, safety, security and resilience, accountability and transparency, explainability and interpretability, privacy enhancement, and fairness with harmful bias managed. It organizes risk-management activities around Govern, Map, Measure, and Manage functions (National Institute of Standards and Technology, 2023b). WHO health AI publications also emphasize ethics and governance themes for AI in health, including risks associated with large multimodal models (World Health Organization, n.d.-a, n.d.-b).

For a medical practice, governance evidence may include an AI tool inventory, approved use cases, vendor review, human oversight rules, prohibited uses, privacy and cybersecurity review, audit logs, quality review, escalation procedures, incident response, and training. A valuation analyst should not treat a policy binder as value by itself. Governance matters when it makes the cash flow more reliable, the workflow more transferable, and the risk profile clearer.

Visual aid 2: Multiple-expansion readiness scorecard

This scorecard is a qualitative preparation tool. It does not calculate a valuation multiple and does not guarantee a premium.

Readiness area	Stronger signal for valuation support	Weaker signal that may create diligence risk	Owner preparation step
Adoption	Providers and staff consistently use the tools; usage logs support trend	Software purchased but rarely used	Export utilization data and training records
Revenue evidence	Telehealth or AI workflow ties to collections, retention, productivity, or A/R improvement	Management asserts a “technology premium” with no financial bridge	Build monthly KPI-to-financial schedules
Reimbursement durability	Payer support, low denials, clean documentation, and monitored policy changes	Revenue depends on temporary or unclear reimbursement	Recheck payer policies and denial history
EHR and billing integration	Data flows into EHR, billing, patient portal, and reporting systems	Manual workarounds and inconsistent coding	Document interfaces and reconciliation process
AI governance	Policies, human oversight, audit logs, model/vendor review, and approved use cases	Unapproved generative AI or black-box workflows	Adopt governance and review protocols
Privacy and security	Current risk assessment, access controls, incident response, vendor review	No risk analysis or unresolved incidents	Compile security documentation and remediation plan
Vendor transferability	Assignable contracts, export rights, clear pricing, and service continuity	Nonassignable licenses or unknown renewal pricing	Review vendor contracts with counsel
Scalability	Workflows can extend to more locations or providers	One internal champion operates the tool informally	Standardize SOPs and training
Buyer comparability	Digital operations resemble buyer/platform standards	Tools conflict with buyer systems	Prepare integration and data-migration file

Valuation methods for telehealth- and AI-enabled medical practices

Income approach and discounted cash flow

The income approach focuses on expected future economic benefits. A discounted cash flow model can be especially helpful when telehealth or AI adoption is changing the practice’s future trajectory. Historical earnings may not show the full benefit or cost of the initiative. DCF can model ramp-up, payer uncertainty, adoption, recurring software, staffing, cybersecurity investment, capex, working capital, and risk.

For example, a practice may have launched AI documentation six months before the valuation date. Reported trailing EBITDA may include implementation expense but not yet show provider capacity improvement. A DCF model can test whether the expected productivity gain is reasonable, whether provider schedules support it, whether patient demand exists, whether revenue can be collected, and whether recurring costs offset the benefit. The appraiser should not reduce risk merely because AI exists. Risk support should come from durable data, governance, transferability, payer evidence, and operating results.

EBITDA and adjusted EBITDA normalization

EBITDA is commonly discussed in medical practice transactions, but it requires careful normalization. Technology-related adjustments can go both directions. A one-time platform conversion, data migration project, or temporary duplicate software cost may be a valid add-back if documented and nonrecurring. Recurring subscriptions, cybersecurity monitoring, support staff, documentation QA, vendor renewal pricing, coding audits, and replacement labor required to sustain the digital model usually should remain in normalized EBITDA.

The same is true for owner compensation. A physician-owner who uses telehealth or AI to see more patients but is paid below market may create overstated EBITDA. A valuation should normalize provider compensation, administrative support, and post-closing staffing requirements before applying a multiple or forecasting cash flow.

Market approach without unsupported multiple ranges

The market approach uses comparable transaction or company evidence when it is reliable and comparable. Digital capability can affect comparability if the subject practice has different technology maturity, payer mix, telehealth utilization, cybersecurity posture, AI governance, recurring costs, scalability, and integration readiness from the guideline evidence. However, public multiple commentary can mislead because it often does not disclose EBITDA definition, owner compensation, working capital, debt/cash treatment, rollover equity, earnouts, buyer type, specialty mix, or digital maturity.

The clean formula is simple:

Enterprise value indication = normalized EBITDA × selected market multiple

The difficult part is selecting the multiple. A selected market multiple must be supported by reliable comparable evidence and subject-company risk analysis. This article intentionally does not publish generic medical-practice, telehealth, AI, or specialty-specific multiple ranges because the verified source base does not support a universal premium.

Asset approach and digital assets

The asset approach may matter when earnings are weak, the practice is newly digitized, technology assets are material, or a transaction carves out assets. It may include medical equipment, AI-enabled devices, telehealth hardware, servers, cybersecurity systems, capitalized software where accounting treatment supports it, EHR data and patient records subject to law, vendor contracts, data export rights, working capital, and liabilities.

For a profitable going concern, the asset approach alone may miss intangible value from patient relationships, assembled workforce, referral networks, systems, brand, and provider reputation. Still, it can be important for reconciling digital infrastructure, debt, equipment financing, working capital, and excluded assets.

Visual aid 3: Valuation method decision tree

This decision tree is educational. It does not replace professional judgment or the standards applicable to a specific valuation engagement. NACVA standards, AICPA VS Section 100, IVSC resources, USPAP resources, and IRS valuation resources all support the broader idea that valuation work should be scoped, documented, and supported by evidence, while the exact standard framework depends on the engagement and professional involved (AICPA & CIMA, n.d.; International Valuation Standards Council, n.d.; National Association of Certified Valuators and Analysts, n.d.; The Appraisal Foundation, n.d.; Internal Revenue Service, n.d.).

Building a defensible adjusted EBITDA bridge for a technology-enabled practice

Start with clean financial and operational records

Before arguing for a technology-related multiple benefit, the practice should build a clean EBITDA bridge. The appraiser will typically request historical financial statements, tax returns, general ledger detail, monthly revenue and expense reports, provider productivity, payer mix, accounts receivable aging, denial reports, telehealth revenue by payer and provider, software contracts, cybersecurity costs, implementation invoices, and owner compensation detail. The EHR and practice-management reports should reconcile to accounting revenue where possible.

Clean records do not guarantee a higher valuation. They reduce uncertainty and help the business appraisal distinguish between actual earnings, nonrecurring costs, recurring costs, and management claims.

Identify technology adjustments that may increase EBITDA

Technology-related adjustments that may increase normalized EBITDA can include documented one-time items such as:

• Initial EHR, telehealth, or AI implementation consulting.
• One-time data migration or interface setup.
• Nonrecurring training during launch.
• Temporary duplicate software during platform conversion.
• A one-time remediation project after a failed vendor transition.
• Nonrecurring workflow consulting tied to a completed conversion.

Each adjustment should be supported by invoices, contracts, general ledger detail, project timelines, and management explanations. A buyer or appraiser may reject an add-back if the cost is recurring, necessary to sustain operations, poorly documented, or likely to recur after closing.

Identify technology costs that should usually stay in EBITDA

Recurring costs usually belong in normalized EBITDA and free cash flow. Common examples include:

• Telehealth platform subscriptions.
• AI documentation or coding subscriptions.
• Ongoing IT support and cybersecurity monitoring.
• Access management, backups, endpoint security, and incident response resources.
• Documentation QA and coding audits.
• Staff time for patient messaging, remote monitoring, escalation, and portal support.
• Vendor renewal price increases, hosting, hardware maintenance, and service fees.
• Compliance review needed to sustain the workflow.

If the practice removes these costs as add-backs but expects the buyer to continue receiving the digital benefits, the EBITDA bridge is likely overstated.

Visual aid 4: Adjusted EBITDA bridge calculation block

Illustrative technology-enabled medical practice EBITDA bridge
(educational example only; not a benchmark, not market evidence, and not a pricing rule)

Reported practice operating income before owner distributions          $900,000
+ Interest expense                                                      40,000
+ Depreciation and amortization                                        110,000
+ Documented one-time EHR/telehealth implementation consulting          75,000
+ Temporary duplicate software during platform conversion               30,000
+ Nonrecurring data migration and staff launch training                 45,000
- Recurring telehealth platform subscription required going forward     (48,000)
- Recurring AI documentation/coding QA and cybersecurity support        (70,000)
- Replacement physician/admin time needed to sustain workflows          (95,000)
= Illustrative normalized EBITDA                                      $987,000

This hypothetical example shows why technology can increase or decrease normalized EBITDA. The reported profit does not tell the full story. The adjustment must distinguish nonrecurring conversion cost from recurring technology and labor cost. Only after EBITDA is normalized should a valuation analyst consider DCF, market approach evidence, or method reconciliation.

Discounted cash flow modeling for telehealth and AI initiatives

Why DCF can be stronger than a headline multiple

A headline multiple is a shortcut. DCF forces the analyst to model the underlying economics. That can be useful when a practice has launched digital tools but historical results are incomplete, when payer policy is uncertain, when adoption is still ramping, or when the buyer is underwriting future improvements.

A DCF model can separately analyze revenue growth, provider capacity, payer mix, collections, denial risk, staffing cost, software subscriptions, cybersecurity investment, capital expenditure, working capital, and terminal-state assumptions. It can also compare base, upside, and downside scenarios. If telehealth adoption is durable and profitable, the DCF should show that. If AI subscriptions cost more than the measured efficiency gain, the DCF should show that too.

Visual aid 5: DCF assumption comparison table

DCF input	Baseline evidence to request	Digitally enabled scenario question	Valuation implication
Revenue growth	Historical visits, collections, payer mix	Does telehealth create incremental visits or only substitute modality?	Forecast revenue and terminal-state growth
Provider capacity	Provider schedules, note completion, staff support	Does AI reduce nonclinical time enough to increase billable capacity?	Margin and revenue assumptions
Reimbursement	Payer contracts, CMS/KFF context, denials	Are telehealth collections durable and properly documented?	Revenue risk and discount-rate support
Recurring software cost	Vendor contracts, renewal terms, invoices	Are subscription costs fully reflected?	EBITDA and free cash flow
Implementation ramp	Launch timeline, training records, adoption data	How long until benefits appear in actual results?	Timing of cash flows
Cybersecurity and privacy	Risk assessment, controls, incident history	Are remediation costs or incidents likely?	Risk, capex, and reserves
Interoperability	EHR interfaces, data export, information-sharing process	Can a buyer integrate data without major cost?	Buyer confidence and integration risk
Capex and working capital	Hardware, devices, accounts receivable, billing lag	Does digital expansion require reinvestment or longer cash cycles?	Free cash flow and equity value

Scenario analysis matters

A digital-health DCF should not have only one forecast. It should test what happens if payer reimbursement changes, patient adoption slows, providers resist a new workflow, denial rates rise, subscription pricing increases, cybersecurity spending is required, or a buyer must replace the vendor. The downside case is not pessimism; it is part of supportable valuation work. A practice with strong controls and durable results may show a narrower risk range. A practice with weak evidence may require a wider risk range.

Market approach: using comparability instead of unsupported multiple claims

What a comparable medical practice transaction must show

The market approach can be useful when comparable transaction evidence is available, but comparability is the central issue. A comparable practice should be analyzed for:

• Specialty and service-line mix.
• Revenue and EBITDA scale.
• Provider dependence and owner transition.
• Payer mix and reimbursement environment.
• Telehealth utilization and collections.
• AI and digital-health maturity.
• EHR, billing, and reporting integration.
• Cybersecurity and privacy posture.
• Normalized EBITDA definition.
• Working capital, debt, cash, earnouts, rollover equity, and contingent consideration.
• Buyer type, transaction date, and deal structure.

If a claimed comparable does not disclose those facts, it may not support a precise multiple. Public commentary can be especially problematic because headline multiples may reflect buyer-specific synergies, rollover equity, employment compensation, earnouts, or strategic scarcity rather than a transferable valuation multiple.

Visual aid 6: Market approach comparability table

Comparability factor	Why it matters for telehealth/AI-enabled practices	Seller data to prepare	Drafting guardrail
Specialty and service mix	Telehealth and AI use cases differ by specialty	Revenue by provider, service, and modality	Do not imply one specialty always receives a premium
EBITDA definition	Technology add-backs and recurring costs change the denominator	EBITDA bridge, GL detail, contracts	No unsupported adjusted EBITDA
Telehealth revenue durability	Temporary or payer-specific reimbursement may not transfer	Payer policies, denial history, collections	Do not generalize Medicare to all payers
AI maturity	Governed workflows differ from ad hoc tools	Policies, logs, training, vendor review	Do not treat the AI label as value
Interoperability	Buyer integration cost affects economics	EHR interfaces, data export terms	Do not assume seamless integration
Cybersecurity and privacy	Weak controls can create diligence issues	Risk assessment, incident history	No legal conclusion; refer to counsel
Deal structure	Headline value may include contingent or noncash consideration	LOI and term comparison	Do not equate multiple with cash proceeds
Buyer type	Strategic synergies may be buyer-specific	Buyer universe and offer context	Do not convert investment value into fair market value automatically

Why unsupported public multiple commentary can hurt an owner

Owners sometimes enter negotiations with an internet multiple in mind. That can backfire. If the multiple ignores provider compensation, revenue quality, payer risk, recurring technology costs, working capital, deal structure, and buyer-specific synergies, the owner may anchor expectations to a number that a buyer or appraiser cannot support. A stronger strategy is to prepare the evidence that justifies why the subject practice is lower risk or higher quality than a less mature practice.

Telehealth and AI can help that argument, but only through documented economics. A clean utilization report, denial trend, vendor transferability memo, AI governance policy, cybersecurity remediation record, and EBITDA bridge may do more for credibility than a broad claim that “AI practices trade at a premium.”

Asset approach, digital infrastructure, and enterprise-to-equity value

Tangible and intangible assets to schedule

A technology-enabled medical practice should maintain a detailed asset and contract schedule. Items may include:

• Medical equipment and diagnostic devices, including AI-enabled devices where applicable.
• Telehealth hardware, cameras, carts, tablets, patient-monitoring devices, and peripherals.
• Servers, networking equipment, backups, endpoint management, and cybersecurity tools.
• Capitalized software or implementation costs where accounting treatment supports it.
• EHR data, patient records, templates, analytics workflows, and reporting systems, subject to law and contracts.
• Vendor contracts, data export rights, termination provisions, renewal pricing, assignment provisions, and service levels.
• Trained workforce, SOPs, AI governance policies, and documented workflows.
• Accounts receivable, working capital, prepaid software, deposits, equipment financing, and liabilities.

The asset approach may receive more weight for a startup practice, a newly digitized practice without stable earnings, a practice with weak EBITDA but material infrastructure, or a transaction where assets are carved out. It may receive less weight for a mature profitable going concern where goodwill, patient relationships, referral networks, and workforce value are captured better by income and market evidence.

Visual aid 7: Enterprise-value-to-equity-value adjustment block

Illustrative enterprise-to-equity bridge for a technology-enabled practice
(educational example only; not tax, legal, transaction, or market-multiple advice)

Indicated enterprise value from valuation analysis                 $7,500,000
- Interest-bearing equipment and technology debt                    (600,000)
- Required cybersecurity remediation identified in diligence         (150,000)
+ Cash retained by seller or added per agreement                     200,000
+/- Working-capital true-up                                          (125,000)
- Escrow/holdback or unresolved billing reserve                      (300,000)
= Illustrative equity value before taxes/fees/deal terms           $6,525,000

Analyze separately:
- Rollover equity or contingent consideration
- Earnouts tied to telehealth/AI performance
- Seller notes
- Taxes and transaction expenses
- Excluded real estate, equipment, or software contracts
- Post-closing employment compensation

This bridge highlights a common owner misunderstanding. A higher enterprise value indication does not always equal higher seller proceeds. Technology debt, cybersecurity remediation, working capital, billing reserves, earnouts, and deal structure can materially affect equity value and cash at closing.

Compliance, cybersecurity, AI governance, and interoperability diligence

FDA and clinical decision support scope

The valuation analyst should not make legal determinations about FDA status. However, the analyst should identify whether a tool may involve AI-enabled medical devices or clinical decision support that requires specialized diligence. FDA sources can help advisers understand that certain AI-enabled devices have been authorized for marketing and that software function classification can be fact-specific (U.S. Food and Drug Administration, n.d.-a, 2026). If a tool is central to a service line, valuation should consider contracts, authorization documentation, service history, quality review, training, and transferability.

ONC, interoperability, and health IT safety

Health IT diligence can influence value because data quality and interoperability affect buyer integration. ONC’s HTI-1 Final Rule page describes certification program updates, algorithm transparency, and information sharing, including provisions that advance interoperability and transparency where applicable (Office of the National Coordinator for Health Information Technology, n.d.-a). ONC’s SAFER Guides support EHR safety self-assessment themes such as clinical decision support, test result follow-up, clinician communication, contingency planning, and organizational responsibility (Office of the National Coordinator for Health Information Technology, 2026). ONC information-blocking resources also provide context for data access and interoperability issues (Office of the National Coordinator for Health Information Technology, n.d.-b).

A practice valuation should not treat every ONC topic as universally applicable to every private practice workflow. The point is diligence. A buyer may ask whether data can be exported, whether EHR interfaces are documented, whether patient communications are reliable, whether downtime procedures exist, and whether certified health IT issues apply.

Privacy, cybersecurity, and ePHI safeguards

Cybersecurity can affect medical practice valuation because it influences business continuity, remediation cost, privacy risk, insurance, vendor access, buyer confidence, and ePHI safeguards. The FTC Health Breach Notification Rule is relevant context for certain health apps and connected digital tools, although applicability is fact-specific and not a substitute for HIPAA or state-law analysis (Federal Trade Commission, n.d.). NIST SP 800-66r2 is a cybersecurity resource guide for implementing the HIPAA Security Rule; it describes the Security Rule’s focus on safeguarding ePHI and provides practical guidance around risk assessment, risk management, and administrative, physical, and technical safeguards (Marron, 2024).

From a valuation perspective, the question is not simply whether the practice “has cybersecurity.” The question is whether risk analysis, remediation, access controls, incident response, backups, vendor management, and staff training are documented well enough to reduce uncertainty. Unresolved incidents or missing risk documentation can become valuation discounts, reserves, deal conditions, or remediation costs.

Visual aid 8: Digital risk matrix — what can erase a technology premium

Risk	Why buyers/appraisers care	Evidence to request	Possible valuation effect
Reimbursement change	Telehealth revenue may not be durable	Payer policies, CMS updates, denials	Lower forecast growth or higher risk
Billing/coding weakness	Revenue may be overstated or repayable	Coding audits, denial reports, refunds	EBITDA reduction or reserve
Clinician resistance	Tools may not survive post-closing	Usage logs, surveys, turnover, training	Lower transferability
Patient complaints	Digital workflow may harm retention	Complaint logs, portal metrics, reviews	Higher churn or lower growth
Vendor lock-in	Buyer may face migration cost	Contracts, assignability, data export	Capex or integration adjustment
Cybersecurity incident	ePHI and continuity risk	Risk assessment, incident history	Risk discount or remediation cost
Weak AI governance	Unreliable output, bias, privacy, or oversight risk	Policies, human review, audit logs	Higher operational uncertainty
Nontransferable data	Buyer cannot use systems effectively	Data maps, interfaces, export rights	Lower scalability or integration value
Unsupported add-backs	EBITDA is overstated	Invoices, contracts, GL detail	Lower normalized EBITDA
Regulatory scrutiny	Deal timing or structure may change	Counsel review, buyer profile	Scenario or closing-risk adjustment

This matrix is not a compliance opinion. It is a valuation risk framework for identifying evidence that can support or undermine a digital premium.

Technology and compliance data-room checklist for a medical practice valuation

Financial and valuation records

• Three to five years of tax returns.
• Annual and monthly profit and loss statements.
• Balance sheets.
• General ledger detail.
• Trailing twelve-month financials.
• Provider productivity reports.
• Payer mix and reimbursement schedules.
• A/R aging, denial reports, refunds, recoupments, and write-offs.
• Debt, equipment financing, software financing, and lease schedules.
• Capital expenditure history and forecast.
• Owner compensation, distributions, and related-party transactions.

Telehealth records

• Telehealth revenue by month, provider, specialty, payer, and service.
• Virtual visit counts and percentage of total visits.
• In-office versus virtual collection and denial rates.
• Telehealth documentation templates and billing policies.
• Patient consent workflows where applicable.
• Scheduling reports, no-show/cancellation trends, and patient complaints.
• Remote monitoring protocols, enrollment, adherence, collections, and staffing.
• Payer policy files and reimbursement correspondence.

AI and digital-health records

• Inventory of AI tools and digital-health platforms.
• Use cases: administrative, documentation, coding, clinical decision support, triage, imaging/device, analytics, patient messaging, or generative AI.
• Vendor contracts, renewal pricing, assignment terms, termination terms, and data export rights.
• FDA/device or clinical decision support classification diligence where relevant.
• AI governance policies, human oversight, audit logs, testing, and incident procedures.
• Training records and user adoption reports.
• Quality assurance reviews and coding audit results.
• Model/vendor risk assessments where available.

Health IT, interoperability, privacy, and cybersecurity

• EHR/practice-management system inventory and interface map.
• Data export and migration plan.
• Certified health IT documentation where applicable.
• Information-sharing and data-access policies where applicable.
• HIPAA Security Rule risk analysis and risk management documentation where applicable.
• Access controls, MFA, backups, contingency plans, and incident-response plans.
• Cybersecurity vendor reports and remediation status.
• Vendor security documentation and business associate documentation where applicable.
• Breach or incident history and counsel/compliance adviser notes.

Buyer integration and transferability

• SOPs for digital workflows.
• Staff roles and responsibilities.
• Provider adoption by user and location.
• Patient communications and brand implications.
• Multi-location standardization plan.
• Data-room permission protocols.
• Transition services needed after closing.
• Integration costs already incurred versus costs still required.

Hypothetical case studies

Case study 1: Behavioral health practice with durable telehealth workflows

A multi-provider behavioral health practice uses telehealth for many appropriate follow-up visits. It tracks collections by modality, monitors payer policies, documents no-show trends, and uses an integrated EHR workflow. Providers consistently use the same templates and the practice can show virtual visit collections, denial rates, and patient retention by month.

In valuation, telehealth may support revenue durability and provider capacity if the payer support, patient demand, documentation, and transferability are credible. DCF can model base, upside, and downside reimbursement scenarios. The market approach may consider comparable evidence only if the guideline practice has similar maturity, modality mix, and risk. No numeric premium should be assumed without reliable transaction support.

Case study 2: Primary care group with remote monitoring but weak reimbursement tracking

A primary care group enrolls patients in remote monitoring but cannot reconcile enrollment, adherence, staff time, denials, collections, and payer policy by program. Providers believe the program is clinically helpful, but the accounting records do not isolate revenue or recurring costs.

In valuation, the remote monitoring initiative may be treated conservatively. The appraiser may include recurring software and staff costs, make limited or no revenue growth adjustment, and build a downside DCF case until the practice produces better evidence. The program could become a value driver later, but weak data prevents it from supporting a multiple premium now.

Case study 3: Specialty practice using AI-enabled imaging support

A specialty practice uses an AI-enabled imaging-support workflow. The practice maintains vendor files, device documentation, quality review, service-line revenue, training records, and provider oversight records. It also tracks equipment/software cost, service volume, and transferability terms.

In valuation, the tool may support service-line economics if it contributes to revenue, margin, or quality of workflow and if contracts and documentation transfer. FDA-source documentation may support diligence, but it does not establish a valuation premium by itself. The asset approach may receive more attention if equipment or software infrastructure is material.

Case study 4: Medical group with ambient documentation but no measurable productivity gain

A medical group adopts ambient documentation. Providers like the idea, but schedules, note-completion time, patient throughput, coding quality, and staff costs do not improve. Subscription and QA costs continue each month.

In valuation, the AI tool may be a cost, not a premium. The appraiser should include recurring subscription and QA costs in EBITDA. If the practice cannot show improved productivity or lower risk, the market approach should not reward the AI label. A DCF model may include an upside case only if credible evidence suggests future adoption improvements.

Case study 5: Multi-location practice with strong digital systems but weak cybersecurity documentation

A multi-location practice has standardized telehealth, patient portal, EHR, and analytics workflows. Buyer diligence is impressed by dashboards and consistent provider adoption, but cybersecurity risk assessments, incident-response documentation, and vendor security files are incomplete.

In valuation, operational scalability may support buyer interest, but privacy and security uncertainty can offset digital benefits. A buyer may require remediation, escrow, indemnity, or purchase price adjustment. The practice can preserve credibility by documenting risk analysis, remediation, vendor review, backups, access controls, and incident procedures before going to market.

Owner preparation roadmap: 6 to 24 months before using telehealth or AI as a valuation story

Twelve to twenty-four months before valuation or buyer outreach

Start by standardizing financial reporting and monthly KPI dashboards. Track telehealth visits by provider, location, payer, service category, and month. Track AI tool adoption by provider or staff user. Review payer policies, coding, documentation, and denials with qualified advisers. Build an AI governance file and cybersecurity documentation before a buyer asks. Review vendor contracts for assignment, data export, renewal pricing, termination, service-level terms, and business associate obligations where applicable. Establish quality review for documentation, coding, patient communications, and escalation protocols.

This early work allows the practice to collect trend data. A one-month improvement is weak support. A consistent trend over a longer period is more persuasive.

Six to twelve months before valuation

Build the adjusted EBITDA bridge. Separate one-time implementation costs from recurring operating costs. Prepare DCF inputs for telehealth and AI scenarios. Document provider capacity, patient access, no-shows, cancellations, referral conversion, patient retention, denials, A/R days, and staff productivity. Identify data gaps that may weaken a market approach. Ask a valuation professional to review whether the practice has enough evidence to support a digital value story.

This is also the right time to clean up contracts. If the telehealth platform, AI tool, EHR interface, or remote monitoring vendor cannot transfer to a buyer, the value implication may be negative even if the workflow works today.

Thirty to ninety days before buyer diligence

Assemble the technology and compliance data room. Recheck current Medicare and payer telehealth policies if relevant to revenue. Update cybersecurity and risk assessment documentation. Confirm vendor contract assignment and data export processes. Review AI governance, human oversight, audit logs, and incident records. Coordinate with the CPA, healthcare counsel, compliance advisers, coding specialists, technology vendors, and transaction advisers.

A prepared practice can answer diligence questions with evidence instead of explanations. That can improve buyer confidence, reduce surprises, and make the valuation analysis more credible.

How Simply Business Valuation can help

Simply Business Valuation can help medical practice owners and advisers understand whether telehealth and AI initiatives are reflected in normalized EBITDA, discounted cash flow scenarios, market approach comparability, asset approach support, and overall business valuation risk. A professional valuation can organize the financial, operational, and technology evidence into a supportable business appraisal rather than relying on unsupported technology-premium claims.

If you are preparing for a sale, buy-sell event, partner dispute, estate plan, lender request, divorce matter, or strategic planning project, gather the checklist items above and obtain an independent valuation before negotiating from a headline multiple. The strongest valuation story is not “we use AI.” It is “our digital workflows are adopted, measured, compliant with applicable adviser-reviewed requirements, financially supported, and transferable.”

FAQ: telehealth, AI, and medical practice valuation multiples

1. Does adding telehealth automatically increase a medical practice valuation multiple?

No. Telehealth can support value only when utilization, reimbursement, collections, patient retention, provider capacity, and transferability are documented. A practice that cannot show financial or operational benefit may receive no premium. A practice with reimbursement uncertainty, denials, weak documentation, or poor adoption may face a valuation discount.

2. Does using AI automatically make a medical practice worth more?

No. AI must create measurable operational or financial benefit after recurring costs and risk controls. Documentation, coding, scheduling, patient engagement, analytics, or clinical decision support tools may support value if they improve cash flow or reduce risk. Unapproved, poorly governed, or lightly used AI can increase risk.

3. How does telehealth affect EBITDA?

Telehealth may affect EBITDA by increasing visit volume, improving schedule utilization, reducing no-shows, supporting remote programs, or improving patient retention. It may also reduce EBITDA through platform subscriptions, staff support, billing review, denials, cybersecurity, and compliance costs. The valuation should measure net contribution, not gross telehealth revenue alone.

4. How does AI affect EBITDA?

AI may affect EBITDA through documentation efficiency, coding support, revenue-cycle analytics, staff productivity, provider capacity, or reduced administrative burden. The appraiser should deduct recurring AI subscriptions, QA review, training, IT support, cybersecurity, and replacement labor needed to sustain the workflow. AI only improves EBITDA if the benefits exceed those costs.

5. Should a medical practice use discounted cash flow for telehealth and AI initiatives?

Often, yes. DCF is useful when digital initiatives are changing future revenue, margin, investment, working capital, or risk. It allows base, upside, and downside scenarios for reimbursement, adoption, provider capacity, software costs, cybersecurity spending, and buyer integration.

6. Can the market approach capture telehealth and AI value?

Yes, but only with reliable comparable evidence. The market approach can reflect digital maturity if comparable transactions or guideline evidence have similar specialty mix, payer mix, EBITDA quality, digital adoption, governance, cybersecurity, and deal terms. Unsupported internet multiple ranges should not be used as valuation evidence.

7. What evidence does an appraiser need to support a digital premium?

Useful evidence includes telehealth revenue by payer and provider, visit volume by modality, collection and denial rates, usage logs, training records, vendor contracts, data export rights, EHR interfaces, patient retention, no-show trends, coding audits, AI governance policies, cybersecurity documentation, and normalized EBITDA support.

8. What risks can reduce the value of telehealth or AI integration?

Major risks include reimbursement changes, billing errors, weak documentation, cybersecurity incidents, poor adoption, vendor lock-in, nonassignable contracts, incomplete data export rights, patient complaints, AI governance gaps, unsupported add-backs, and buyer integration costs.

9. Are AI-enabled medical tools always FDA-regulated?

No. FDA sources distinguish AI-enabled medical devices and clinical decision support issues, and software-function classification depends on facts and intended use. Medical practices should consult qualified regulatory advisers for specific tools. For valuation, the appraiser should identify the diligence question and evaluate contracts, documentation, transferability, and service-line economics.

10. Do Medicare telehealth rules apply to every payer?

No. Medicare policy is important for Medicare revenue, but it does not control every commercial payer, Medicaid program, state licensure issue, prescribing rule, consent process, privacy obligation, malpractice issue, or corporate-practice question. Payer and legal review should be specific to the practice and valuation date.

11. How does cybersecurity affect medical practice valuation?

Cybersecurity affects valuation through risk, remediation cost, business continuity, insurance, buyer confidence, ePHI safeguards, vendor access, and incident history. Weak documentation can create diligence concern even when no breach has occurred. Strong documentation does not guarantee a premium, but it can reduce uncertainty.

12. Can telehealth and AI assets be valued under the asset approach?

Yes. The asset approach may consider medical equipment, AI-enabled devices, telehealth hardware, servers, cybersecurity systems, software implementation, vendor contracts, data export rights, working capital, and liabilities. For a profitable going concern, the asset approach usually needs to be reconciled with income and market evidence.

13. Is a buyer offer the same as a professional business valuation?

No. A buyer offer may reflect buyer-specific synergies, negotiation strategy, rollover equity, earnouts, employment compensation, financing constraints, or strategic scarcity. A professional business valuation depends on purpose, standard of value, valuation date, subject interest, available evidence, and selected valuation methods.

14. When should a medical practice get a valuation if it is implementing telehealth or AI?

Ideally, the practice should obtain valuation advice after enough operating evidence exists to evaluate adoption and financial impact, or earlier for planning and scenario analysis. Owners should not wait until buyer diligence to discover that telehealth revenue, AI productivity gains, cybersecurity records, or vendor transferability cannot be supported.

References

AICPA & CIMA. (n.d.). Statement on Standards for Valuation Services (VS Section 100). https://www.aicpa-cima.com/resources/download/statement-on-standards-for-valuation-services-vs-section-100

American Medical Association. (2022, September). AMA digital health research: Physicians’ motivations and key requirements for adopting digital health. https://www.ama-assn.org/system/files/ama-digital-health-study.pdf

American Medical Association. (n.d.-a). Augmented intelligence in medicine. https://www.ama-assn.org/practice-management/digital-health/augmented-intelligence-medicine

American Medical Association. (n.d.-b). Recent changes in physician practice arrangements: Shifts away from private practice and towards larger practice size continue through 2022. https://www.ama-assn.org/system/files/2022-prp-practice-arrangement.pdf

Centers for Medicare & Medicaid Services. (n.d.-a). Telehealth. https://www.cms.gov/medicare/coverage/telehealth

Centers for Medicare & Medicaid Services. (n.d.-b). List of Telehealth Services. https://www.cms.gov/medicare/coverage/telehealth/list-services

Cottrill, A., Cubanski, J., & Neuman, T. (2026, March 19). What to know about Medicare coverage of telehealth. KFF. https://www.kff.org/medicare/what-to-know-about-medicare-coverage-of-telehealth/

FAIR Health. (n.d.). Monthly Telehealth Regional Tracker. https://www.fairhealth.org/fh-trackers/telehealth

Federal Trade Commission. (n.d.). Health Breach Notification Rule. https://www.ftc.gov/legal-library/browse/rules/health-breach-notification-rule

Federal Trade Commission. (2024a). Federal Trade Commission, the Department of Justice and the Department of Health and Human Services launch cross-government inquiry on impact of corporate greed in health care. https://www.ftc.gov/news-events/news/press-releases/2024/03/federal-trade-commission-department-justice-department-health-human-services-launch-cross-government

Federal Trade Commission. (2024b). FTC and DOJ seek info on serial acquisitions, roll-up strategies across U.S. economy. https://www.ftc.gov/news-events/news/press-releases/2024/05/ftc-doj-seek-info-serial-acquisitions-roll-strategies-across-us-economy

Federal Trade Commission & U.S. Department of Justice. (2023, December 18). Merger Guidelines. https://www.ftc.gov/system/files/ftc_gov/pdf/2023_merger_guidelines_final_12.18.2023.pdf

Internal Revenue Service. (n.d.). Valuation of assets. https://www.irs.gov/businesses/valuation-of-assets

International Valuation Standards Council. (n.d.). International standards for international markets. https://ivsc.org/standards/

Marron, J. (2024, February). Implementing the Health Insurance Portability and Accountability Act (HIPAA) Security Rule: A cybersecurity resource guide (NIST SP 800-66r2). National Institute of Standards and Technology. https://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-66r2.pdf

National Association of Certified Valuators and Analysts. (n.d.). Professional standards and ethics. https://www.nacva.com/standards

National Institute of Standards and Technology. (2023a). AI Risk Management Framework. https://www.nist.gov/itl/ai-risk-management-framework

National Institute of Standards and Technology. (2023b, January). Artificial Intelligence Risk Management Framework (AI RMF 1.0) (NIST AI 100-1). https://nvlpubs.nist.gov/nistpubs/ai/NIST.AI.100-1.pdf

Office of the National Coordinator for Health Information Technology. (n.d.-a). HTI-1 Final Rule. https://healthit.gov/regulations/hti-rules/hti-1-final-rule/

Office of the National Coordinator for Health Information Technology. (n.d.-b). Information Blocking. https://healthit.gov/information-blocking/

Office of the National Coordinator for Health Information Technology. (2026, February 27). SAFER Guides. https://healthit.gov/clinical-quality-and-safety/safer-guides/

The Appraisal Foundation. (n.d.). USPAP®. https://appraisalfoundation.org/products/uspap

U.S. Food and Drug Administration. (n.d.-a). Artificial intelligence-enabled medical devices. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices

U.S. Food and Drug Administration. (2026, January 29). Clinical Decision Support Software. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software

World Health Organization. (n.d.-a). Ethics and governance of artificial intelligence for health. https://www.who.int/publications/i/item/9789240029200

World Health Organization. (n.d.-b). Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models. https://www.who.int/publications/i/item/9789240084759